Heat shock protein 90 (Hsp90) inhibition by modulation of the N-or C-terminal binding site has become an attractive strategy for the development of anti-cancer chemotherapeutics. The first Hsp90 C-terminus inhibitor, novobiocin, manifested a relatively high IC50 value of ~700 μM. Therefore, investigation of the novobiocin scaffold has led to analogs with improved antiproliferative activity (nanomolar concentrations) against several cancer cell lines. During these studies, novobiocin analogs that do not inhibit Hsp90 were identified; however, these analogs demonstrated potent anti-proliferative activity. Compound 2, a novobiocin analog, was identified as a MAPK pathway signaling disruptor that lacked Hsp90 inhibitory activity. In addition, structural modifications of compound 2 were identified that segregated Hsp90 inhibition from MAPK signaling disruption. These studies indicate that compound 2 represents a novel scaffold for disruption of MAPK pathway signaling and may serve as a useful structure for the generation of new anti-cancer agents.
INTRODUCTION
Heat shock protein 90 (Hsp90) is a molecular chaperone that facilitates the conformational maturation of other cellular proteins, termed clients, via the Hsp90 chaperone cycle. Hsp90 functions as a homodimer and each monomer comprises an N-terminal domain (the site of ATP-binding and hydrolysis), a middle domain, and a C-terminal dimerization domain.
Inhibitors that target the N-and C-termini of Hsp90 can halt client maturation and lead to ubiquitinylation and degradation of the substrate via the proteasome [1] [2] [3] [4] [5] . N-terminal inhibitors perturb ATPase activity at the N-terminus and include derivatives of the natural product geldanamycin. However, N-terminal inhibition also leads to induction of the prosurvival heat shock response (HSR) via Heat Shock Factor-1. This led to the development of C-terminal inhibitors, in which the HSR is avoided and client degradation is maintained. There are several therapeutic opportunities for small molecules that target the Hsp90 N-or Cterminus, including the development of anticancer chemotherapeutics [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] .
Novobiocin is a natural product that inhibits the Hsp90 C-terminus and was found to exhibit an IC50 value of ~700 μM against the SKBr3 breast cancer cell line (Figure 1 ) 21 . Extensive structure-activity relationship (SAR) studies on novobiocin have greatly improved antiproliferative activity against many different cancer cell lines and identified structural elements necessary for Hsp90 inhibition; however, exploration of the amide linker has yet to be fully investigated [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] .
During SAR studies of the urea linker that was probed as a surrogate for the amide, analogues were identified that exhibited potent anti-proliferative activity against several cancer cell lines. However, some of the compounds did not inhibit Hsp90. Investigation of these analogues led to identification of 2, a novobiocin analogue that exhibited potent antiproliferative activity against the MCF7 breast and A549 lung cancer cell lines without Hsp90 inhibitory activity. Instead, compound 2 was shown to disrupt mitogen-activated protein kinase (MAPK) signaling and in a time-dependent manner inhibited the phosphorylation of MEK and ERK. Since oncogenic mutations frequently occur within the MAPK pathway, much research has been devoted to the development of inhibitors of this pathway, including EGFR, Raf, MEK and ERK [41] [42] [43] . Preliminary SAR studies of 2 examined the necessity of each methoxy substitution on the biaryl side chain and identified moieties that transition novobiocin analogues from Hsp90 inhibitory activity, such as compound 1, to MAPK pathway inhibitors ( Figure 1 ).
RESULT AND DISCUSSION
As shown in Scheme 1, compound 1 was prepared in one step by coupling the previously reported aniline 6 39 with the commercially available phenylisocyanate, 7a. Compound 2 was synthesized from biaryl acid 8 39 , using diphenylphosphorylazide to give the corresponding azide, which underwent Curtius rearrangement to afford phenylisocyanate, 7b. Subsequent coupling of 7b with intermediate 6, provided compound 2 in good yield.
Many client proteins that depend upon Hsp90 are up-regulated and oftentimes represent signaling pathways that are hijacked during malignant transformation 16, 18, 44, 45 . Compounds that inhibit Hsp90, or the Hsp90 chaperone cycle, lead to client protein degradation via the ubiquitin proteasome pathway and deprive cancer the use of clients that drive progression and growth 1, 4, 5, 46 . Therefore, decreased client protein levels are observed at the IC50 values obtained in cell proliferation assays for Hsp90 inhibitors. To determine whether a compound inhibits Hsp90, IC50 values are generated against cancer cell lines that depend upon functional Hsp90. The estrogen receptor-expressing MCF7 breast cancer cell line and the KRAS-driven A549 lung cancer cell line both depend upon Hsp90 for client protein maturation. Therefore, compounds that exhibit potent anti-proliferative activity against these cell lines may inhibit Hsp90. Table 1 shows the IC50 values for compounds 1 and 2 generated against these cancer cell lines, as well as the normalized cell line, MRC-5. 1 and 2 were shown to exhibit potent inhibition of cancer cell growth compared to the MRC-5 line, indicating the cellular target(s) for these compounds facilitate cancer growth.
Client protein levels in MCF7 and A549 cells were determined via Western blot analysis after incubation with low and high concentrations of 1 and 2 (L = half the IC 50 value; H = five-times the IC 50 value, respectively; Figure 2 ). If client levels are unaffected upon incubation with low concentrations of the compound and decreased at high concentrations, the compound is likely to inhibit Hsp90 function.
Incubation with high concentrations of 1 led to decreased levels of the Hsp90-dependent clients EGFR, Her2 and C-Raf in both MCF7 and A549 cell lysates, when compared to vehicle control ( Figure 2 ). Hsp90 levels at low and high concentrations of 1 were comparable to vehicle and indicative of Hsp90 C-terminal inhibition 37 . Furthermore, incubation with the N-terminal inhibitor, geldanamycin (GDA), led to decreased client levels at concentrations that increased cellular levels of Hsp90 (Supplementary Figure 1) 47, 48 . These data suggest the mechanism of action manifested by compound 1 is inhibition of the Hsp90 C-terminus, as opposed to N-terminal inhibition.
In contrast, client protein levels were unchanged after incubation with low and high concentrations of 2 against both MCF7 and A549 cells. Since no Hsp90-dependent client protein degradation was observed with compound 2, the data suggests this compound inhibits cancer cell growth unrelated to Hsp90 inhibition. The luciferase refolding activity was measured for the compound 2 to confirm whether this compound has Hsp90 inhibitory activity. The data demonstrates that compound 2 does not inhibit the re-maturation of firefly luciferase, similar to DMSO treated cells (Figure 2 ). In contrast, the novobiocin analog, KU-257, which inhibits Hsp90 39 , was shown to inhibit luciferase re-maturation ( Figure 2 ). These results further confirm that compound 2 inhibits cancer cell growth unrelated to Hsp90 inhibition. Given the potent antiproliferative activity manifested by 2 against both cancer cell lines as well as the selective inhibition of cancer cell growth, the mechanism by which 2 manifests this anti-cancer activity was pursued.
Since 2 exhibited potent anti-proliferative activity against the non-small cell lung cancer cell line A549 and generated an IC50 value of 0.15 ± 0.02 μM, subsequent studies were initiated with this cell line. The A549 cell line expresses wild type B-Raf, C-Raf and mutant KRAS. Proliferation of the A549 cell line is driven by over-activation/expression of proteins involved in the Ras-Raf-MEK-ERK (MAPK) pathway and consequently, this cell line is commonly utilized to identify small molecule kinase inhibitors that target Raf, MEK and/or ERK 49 . Interestingly, many inhibitors that target kinases involved in the MAPK pathway display structural similarities to compound 2 ( Figure 3 ). pathway, it was hypothesized that 2 may inhibit the A549 cancer growth through disruption of MAPK signaling. Therefore, to determine whether 2 inhibits kinases within the MAPK pathway, Western blots for phosphorylated proteins involved in the MAPK pathway were performed using A549 lysates treated with 2 at 750 nM (five-times the IC50 value) for two to 12 hours ( Figure 4A ). Treatment with 2 led to a time-dependent decrease in phosphorylated MEK and ERK suggesting this compound inhibits kinase activity; however, decreased levels of phospho-MEK (p-MEK) and phospho-ERK (p-ERK) were observed at different incubation times. Decreased p-MEK levels occurred after four hours of incubation with 2 and were undetectable after 12 hour incubation. In contrast, decreased p-ERK levels were only observed after six hours of incubation and continued to decrease during the 12 hour incubation. These data indicate that 2 disrupts kinase activity upstream of MEK and ERK; 2 prevented phosphorylation of MEK, which subsequently prevented phosphorylation of ERK. The levels of other proteins crucial for MAPK signaling, such as EGFR and C-Raf, remained constant at each time point and were comparable to vehicle control. C-Raf is an Hsp90 client and undergoes proteolytic degradation upon 12 hours of incubation with Hsp90 inhibitors. After 12 hours of incubation with 2, C-Raf levels were similar to vehicle and remained constant at each time point, which demonstrates that compound 2 inhibits cancer cell growth by a mechanism unrelated to Hsp90 inhibition. Total MEK and ERK levels also remained constant at each time point and were comparable to vehicle, indicating that decreased p-MEK and p-ERK levels were not the result of decreased MEK and ERK levels. To determine whether 2 inhibits general kinase activity, Western blots were generated for phosphorylated Akt (p-Akt) and total Akt levels using A549 cell lysates after two to 12 hours of incubation. Akt is phosphorylated by phosphoinositide 3-kinase (PI3K), and p-Akt formation is unrelated to the MAPK pathway 50 . Supplementary Figure 2 demonstrates that p-Akt and total Akt levels were unaffected at each time point, which suggests that 2 preferentially inhibits phosphorylation of the MAPK pathway proteins. Figure 4B shows a concentration-dependent decrease in p-MEK and p-ERK after 12 hours of incubation with 2. A low concentration of 2 (L; half the IC50 value, 70nM) had little effect on cellular levels of p-MEK and p-ERK; however, incubation with a high concentration of 2 (five-times the IC50 value, 750 nM) resulted in significantly lower levels of p-MEK and pERK, which were consistent with previous observations. Little effect was observed on the levels of other MAPK-associated proteins, as well as total MEK and ERK levels at either concentration.
It is well established that small molecule inhibition of the MAPK pathway activates multiple feed-back mechanisms that ultimately result in up-regulated MAPK pathway activity [51] [52] [53] [54] . In vitro, this occurs at short incubation times and can be observed up to 24 hours after incubation with inhibitors of the MAPK pathway (via increased levels of p-MEK and p-ERK as well as increased transcription of MAPK proteins and proteins that support feed-back mechanisms). Western blot analysis of MAPK pathway proteins, p-MEK and p-ERK from A549 cell lysates treated with high concentrations of 2 (750 nM) for 12 and 24 hours were conducted ( Figure 4B ). After 24 hours of incubation, p-MEK and p-ERK levels were only slightly increased compared to 12 hours of incubation; however, these levels remained lower than vehicle control, which could result from the up-regulation of MAPK pathway activity via a feed-back mechanism or the consequence of compound 2 instability, which may produce metabolites that no longer interact with the cellular target(s).
To determine whether re-establishment of detectable p-MEK and p-ERK levels after 24 hours of incubation with 2 was the result of feed-back mechanism activation, Western blots for Her3 and wild-type B-Raf levels were performed. Her3 and wild type B-Raf are expressed at relatively low levels in cancer cells under normal conditions. However, inhibition of MAPK pathway activity via small molecule EGFR, Raf or MEK inhibitors induce Her3 and wild-type B-Raf overexpression to compensate for decreased p-MEK and p-ERK signaling. After 24 hours of incubation with 2, Her3 and wild-type B-Raf levels were comparable to vehicle and indicated no activation of a feed-back mechanism ( Figure 5 ). Western blots for Her3 and wild-type B-Raf levels from A549 lysates treated with control compounds (sorafenib, vemurafenib and TAK-632) for 12 and 24 hours were also performed ( Figure 5 ). Sorafenib is a kinase inhibitor and incubation with sorafenib at five-times the reported IC50 value (14 μM TAK-632 is a kinase inhibitor that preferentially inhibits wild-type B-Raf and C-Raf, and ultimately leads to decreased p-MEK and p-ERK levels (Supplementary Figure 3) . Her3 and wild-type B-Raf levels remained unaffected after 12 and 24 hours of incubation with TAK-632 at five-times the reported IC50 value (8.5 μM) which is comparable to 2 ( Figure  5 ) 56 . These data indicate that 2 prevents p-MEK and p-ERK formation via a mechanism similar to TAK-632, which targets wild-type B-Raf and C-Raf.
It has been previously reported that Raf inhibitor treatment leads to hetero-dimerization between wild type B-Raf and c-Raf causing re-establishment of MAPK pathway signaling and cancer proliferation 57 . Therefore, a co-immunoprecipitation assay was performed to investigate whether compound 2 activates the MAPK pathway by heterodimer formation. The results provided in Figure 6 demonstrate that 2 does not result in dimerization of wild type B-Raf and c-Raf.
In lieu of the biaryl side chain, the incorporation of a phenyl ring onto the urea linker (1) results in Hsp90 inhibition as observed via client protein degradation (see Figure 2) , while replacement of the phenyl substituent with a bulky di-methoxy biaryl side chain leads to disruption of the MAPK pathway. Therefore, compounds 3, 4 and 5, which contain substitutions about the biaryl side chain were synthesized to identify substitutions that distinguish Hsp90 inhibitory activity from MAPK pathway inhibition (Scheme 2). Compound 3 contains a biaryl side chain with no methoxy groups, while 4 and 5 each contain a single methoxy substitution on the biaryl side chain. IC50 values for each compound were determined against the A549 cancer cell line as shown in Table 2 . Each compound exhibited potent anti-proliferative activity within the nanomolar concentration range.
Western blot analyses for Hsp90 clients were performed using A549 cell lysates dosed for 12 and 24 hours with high concentrations of each compound (five-times the IC50 value) to identify Hsp90 inhibitors ( Figure 7A ). After 24 hours of incubation with 3, decreased levels of Hsp90-dependent client proteins were observed while constant levels of Hsp90 remained, suggesting that 3 is an Hsp90 C-terminal inhibitor. Single methoxy substitutions on the biaryl side chain (4 and 5) did not result in decreased client levels after 12 or 24 hours of incubation, indicating no Hsp90 inhibition. Western blot analyses for MAPK pathway proteins and p-MEK and p-ERK levels were performed using the A549 cell lysates dosed for 12 and 24 hours with 4 and 5 and are shown in Figure 7B . 12 hours of incubation with 4 led to decreased p-MEK and pERK levels compared to vehicle; however in contrast to 2, p-MEK and p-ERK levels were reestablished after 24 hours of incubation with 4 and 5. P-ERK levels were also decreased after 12 hours of incubation with 5; however, 24 hours of incubation resulted in p-ERK levels that were comparable to vehicle. After 12 and 24 hours of incubation with 5, p-MEK levels were unchanged.
These data indicate that both methoxy substitutions on the biaryl side chain are important for prolonged MAPK pathway disruption. While mono-methoxy substitutions inhibited p-MEK and/or p-ERK formation, neither substitution alone was able to sustain inhibitory activity to the extent of the dimethoxy-substituted side chain present in 2.
CONCLUSIONS
In conclusion, 2 was synthesized during SAR studies of novobiocin-based Hsp90 C-terminal inhibitors that contain urea surrogates of the amide linker. 1 was identified as an Hsp90 inhibitor via Hsp90-dependent client degradation, however, 2 failed to exhibit Hsp90 inhibitory activity. Upon further investigation, 2 was shown to disrupt the MAPK pathway signaling by preventing p-MEK formation after 4 hours of incubation, which ultimately disrupted p-ERK formation. Disruption of p-MEK and p-ERK formation was comparable to the control compound TAK-632, a Raf inhibitor that preferentially inhibits wild type B-Raf and C-Raf; however, 2 exerted this activity at one tenth the IC50 value of TAK-632 (IC50 value of 0.15 ± 0.02 μM versus 1.7 μM against the A549 lunger cancer cell line). While individual methoxy substitutions on the biaryl side chain inhibit p-MEK and/or p-ERK formation, the dimethoxy-substituted biaryl sidechain is required for sustained inhibition. Therefore, 2 represents a novel, novobiocin-based scaffold for the development of MAPK pathway inhibitors and appears to manifest a similar mechanism of action to TAK-632 and target C-Raf and wild-type B-Raf.
EXPERIMENTAL SECTION Chemistry
General Methods-1 HNMR were recorded at 400 or 500 MHz (Bruker DRX-400 Bruker with a H/C/P/F QNP gradient probe) spectrometer and 13 C NMR spectra were recorded at 100 or 125 MHz (Bruker DRX 500 a LCT Premier (Waters Corp., Milford, MA) spectrometer. The purity of all compounds was determined to be >95% as determined by HPLC analysis. TLC was performed on glassbacked silica gel plates (Uniplate) with spots visualized by UV light. All solvents were reagent grade and when necessary, were purified and dried by standard methods. Concentration of solvents occurred via the use of a rotary evaporator operating at reduced pressure.
General procedure for the synthesis of urea derivatives: 1-(8-methyl-7-((1-methylpiperidin-4-yl)oxy)-2-oxo-2H-chromen-3-yl)-3-phenylurea (1) Phenyl isocyanate (17 mg, 0.14 mmol) was added to a solution of amine 6 39 (20 mg, 0.07 mmol) in dichloromethane (2 mL) and stirred at r. 
Biology
Antibodies and Reagents: Antibodies targeting Akt 1/2/3 and actin were purchased from Santa Cruz Biotechnology. The antibody targeting Hsp90 was purchased from Thermo Scientific (PA3-013). The following antibodies were purchased from Cell Signaling: EGF Receptor, p44/42 MAPK, P-p44/42 MAPK, MEK1/2, P-MEK1/2, pAkt, BRaf, CRaf, Her3/ ErbB3 and Her2/ErbB2. Geldanamycin was purchased from Sigma Aldrich and sorafinib, vemurafinib and TAK-632 were purchased from Selleckchem.
Cell Culture: the media for each cell line was supplemented with streptomycin (500 μg/mL), penicillin (100 units/mL), and 10% FBS. MCF7 cells were maintained in Advanced DMEM/F12 (1:1; Gibco) supplemented with L-glutamine (2 mM). A549 cells were maintained in F12K (Cellgro). MRC-5 cells were maintained in DMEM (Cellgro). Cells were grown in a humidified atmosphere (37 °C, 5% CO2) and passaged when confluent.
Anti-proliferation: cells were grown to confluence, seeded (2000 cells/well, 100 μL total media) in clear, flat-bottom 96-well plates and allowed to attach overnight. Compound at varying concentrations in DMSO (1% DMSO final concentration) was added. Cells were returned to the incubator for an additional 72 h. After 72 h, cell growth was determined using an MTS/PMS cell proliferation kit (Promega) per the manufacturer's instructions. Cells that incubated in 1% DMSO were used as 100% proliferation (i.e. DMSO = 100% growth) and the relative growth for each compound concentration was compared to 1% DMSO. IC50 values were calculated from two separate experiments performed in triplicate using GraphPad Prism 6.0.
Western Blot: cells were grown to confluence and seeded at 0.4 × 106 cells/well/2 mL. Cells were incubated for 24 hours and treated with compound in DMSO (0.25% DMSO final concentration), or vehicle (DMSO) for the indicated amount of time. Cells were harvested in cold PBS and lysed using MPER (Thermo Scientific) supplemented with protease and phosphatase inhibitors (Roche) according to manufacturer's directions. Lysates were clarified at 14,000g for 15 minutes at 4° C. Protein concentrations were determined using the Pierce BCA protein assay kit per the manufacturer's instructions. Equal amounts of protein (15 μg) were electrophoresed under reducing conditions (10% acrylamide gels), transferred to PVDF, and immunoblotted with the corresponding antibody. Membranes were incubated with an appropriate horseradish peroxidase-labeled secondary antibody, developed with a chemiluminescent substrate, and visualized.
Co-immunoprecipitation: A549 cell lines were plated in 10 cm cell culture dishes or T25 flasks and allowed to grow to ~80% confluency. A549 cell lines were received DMSO (0.1%) (Vehicle), or the indicated drugs dissolved in DMSO at indicated concentrations for 24 h. After drug treatments A549 cell lines were harvested in lysis buffer containing 0.1% NP40, 50 mM Tris (pH 7.5), 150 mM NaCl, protease and phosphatase inhibitor cocktails (Roche). Lysates were clarified and protein concentration was determined using BCA assay. For co-immunoprecipitation, 500 μg of total protein was diluted to 500 μL total volume in lysis buffer and incubated with 10 μl of primary antibody overnight at 4 °C with rocking.
Immune complexes were captured with 30 μL of DynaBeads Protein G (Invitrogen) for 3 h with rocking at 4 °C. Protein G Bead complexes were washed three times with lysis buffer and eluted with sample buffer. Samples were then boiled and subjected to SDS-PAGE and Western blot analysis.
Luciferase Refolding Assay: Compound at varying concentrations in DMSO (1% DMSO final concentration) was added to wells of a white, round-bottom 96-well plate containing 50 μL of DMEM media. Luciferase-expressing PC3-MM2 cells were grown to confluence, collected, and incubated for 8-12 min at 50 °C in pre-warmed DMEM media until bioluminescence of luciferase was reduced to 1% of the initial counts. Cells were added (60,000 cells/50 μL) to wells (final concentration of 60,000 cells/100 μL), and the plate was returned to the incubator for 1 h. After 1 h, 100 μL of luciferase substrate reagent (75 mM tricine at pH7.8, 24 mM MgSO 4 , 0.3 mM EDTA, 2 mM DTT, 0.313 D-luciferin, 0.64 mM coenzyme A, 0.66 mM ATP, 150 mM KCl, 10% Triton-X, 20% glycerol, and 3.5% DMSO) was added to wells, and the bioluminescence was immediately read (0.5 s integration time). Cells that were incubated in 1% DMSO were used as 100% bioluminescence (i.e., DMSO = 100% refolding), and the relative refolding for each compound concentration was compared to that in 1% DMSO. The concentrations for each compound were in triplicate, and doseresponse curves were generated using GraphPad Prism 5.0.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. Structures and the overlay of compound 2 (green) with sorafenib (gray; a kinase inhibitor that targets B-Raf and C-Raf), TAK-632 (magenta; a kinase inhibitor that targets C-Raf and wild-type B-Raf) and with vemurafenib (yellow; an inhibitor of mutant B-Raf). 
